Table 2 Safety and efficacy results from clinical trials of blinatumomab
From: Recent updates for antibody therapy for acute lymphoblastic leukemia
Type | R/R Ph− | R/R Ph+ | MRD+ | |||
|---|---|---|---|---|---|---|
Ref | [44] | [43] | [45] | [46] | [48] | [49] |
Regimen | BLN | BLN | BLNvs SOC | BLN | BLN | BLN |
Capacity | 36 | 189 | 405 | 45 | 21 | 116 |
 ≥ second salvage | 21% | 39% | 45% | 82% |  | 36% |
Response | CR/CRh: 69% | CR/CRh: 43% | CR: 34% CR/CRh/ CRi: 44% | CR: 31% CR/CRh: 36% | MRD response: 80% | MRD response: 78% |
OS (median) | 9.8 | 6.1 | 7.7 | 7.1 | – | 36.5 |
Grade3 + neurotoxity | 16% | 11% | 9% | 7% | 19% | 13% |
Grade3 + CRS | 6% | 2% | 5% | 0% | 0% | 2% |